ライフサイエンスコーパス: brucellosis

1 nch fever, epidemic typhus, and Malta fever (brucellosis).

2 t intracellular bacterial infections such as brucellosis.

3 disease is a frequent complication of human brucellosis.

4 luding B regulatory functions, during murine brucellosis.

5 rucella suis is a causative agent of porcine brucellosis.

6 ooded land and marine vertebrates and causes brucellosis.

7 viable candidates as vaccine strains against brucellosis.

8 woman with clinical symptoms consistent with brucellosis.

9 or use in future vaccination studies against brucellosis.

10 onic, and often lifelong, infection known as brucellosis.

11 r investigated as a vaccine to prevent human brucellosis.

12 n, and to investigating adaptive immunity in brucellosis.

13 e elicitation of protective immunity against brucellosis.

14 (febrile illness and single SAT titre >=160) brucellosis.

15 ant widely used as a live vaccine for bovine brucellosis.

16 ore important roles in the control of murine brucellosis.

17 r investigated as a vaccine to prevent human brucellosis.

18 igenic specificity of protective immunity to brucellosis.

19 antibody in the tube agglutination test for brucellosis.

20 r the laboratory confirmation of acute human brucellosis.

21 bacterial pathogen Brucella spp. that cause brucellosis.

22 and epidemiological concerns associated with brucellosis.

23 , which suggests the additional diagnosis of brucellosis.

24 mory T cells, also confer protection against brucellosis.

25 ternative means to elicit protection against brucellosis.

26 cine safety and further study osteoarticular brucellosis.

27 frequently affected in patients with active brucellosis.

28 mechanisms of liver damage observed in human brucellosis.

29 tter understanding of focal complications of brucellosis.

30 with histories and findings consistent with brucellosis.

31 gical agent of the zoonotic disease known as brucellosis.

32 ntify mediators of focal inflammation during brucellosis.

33 esis-informed rationales to prevent or treat brucellosis.

34 to obtain an effective human vaccine against brucellosis.

35 some potential mechanisms of liver damage in brucellosis.

36 mechanisms of liver damage observed in human brucellosis.

37 en acute human brucellosis and chronic human brucellosis.

38 luation of therapeutics against inhalational brucellosis.

39 s into the fundamental immunopathogenesis of brucellosis.

40 ard the development of improved vaccines for brucellosis.

41 acultative intracellular bacteria that cause brucellosis, a chronic debilitating disease significantl

42 racellular gram-negative bacteria that cause brucellosis, a common global zoonosis.

43 Brucella abortus is the causative agent of brucellosis, a debilitating disease that affects humans

44 h authorities, and legislators who deal with brucellosis, a disease that is particularly relevant in

45 a consists of bacterial pathogens that cause brucellosis, a major zoonotic disease characterized by u

46 ultative intracellular bacterium that causes brucellosis, a prevalent zoonosis that leads to abortion

47 Since presumptive diagnosis of brucellosis, a serious disease in domestic livestock, wi

48 cultative intracellular parasites that cause brucellosis, a severe animal and human disease.

49 cultative intracellular pathogen that causes brucellosis, a worldwide zoonosis that affects a wide ra

50 Brucella species are responsible for brucellosis, a worldwide zoonotic disease causing aborti

51 cella spp., as animal pathogens, cause human brucellosis, a zoonosis that results in worldwide econom

52 The control of brucellosis across sub-Saharan Africa is hampered by the

53 tuberculosis, rheumatic fever, leprosy, and brucellosis, although more common in the tropics, contin

54 inable diseases in urban areas (for example, brucellosis among zoonotic: IRR 0.516, 95% CI [0.498, 0.

55 tubes from 17 patients with acute serologic brucellosis and 3 patients with chronic relapsing brucel

56 opathogenetic mechanisms between acute human brucellosis and chronic human brucellosis.

57 lls obtained from the blood of patients with brucellosis and control individuals.

58 sts play an important role in osteoarticular brucellosis and could serve as a useful in vitro model f

59 L2rgamma(null) mouse to study osteoarticular brucellosis and examined the potential use of this strai

60 se and human brucellosis) and animal (bovine brucellosis and foot-and-mouth disease) infections clear

61 rucella suis is the causative agent of swine brucellosis and is known to be able to infect several di

62 = 1.11 (95% CI = 1.02-1.21) in herds without brucellosis and lambda = 1.00 (95% CI = 0.85-1.16) when

63 0.034), but there was no association between brucellosis and pregnancy or being observed with a calf.

64 pread of diseases and occupational risks for brucellosis and psittacosis were identified.

65 We describe the neurological involvement in brucellosis and revisited diagnostic criteria for neurob

66 diagnosis of human (Chagas disease and human brucellosis) and animal (bovine brucellosis and foot-and

67 rB8 of Brucella suis, the causative agent of brucellosis, and ComB10, a VirB10 homolog of Helicobacte

68 ensus about the optimum therapy for vascular brucellosis, and the urgent need for additional studies

69 Rift Valley fever (RVF) and brucellosis are serious zoonotic diseases with significa

70 cally distinct African lineage and reinforce brucellosis as a major concern for both animal and publi

71 This report emphasizes the need to consider brucellosis as a part of the differential diagnosis of a

72 llosis and 3 patients with chronic relapsing brucellosis as determined by serologic tests and the pat

73 The World Health Organization describes brucellosis as one of the world's leading zoonotic disea

74 n additional patients with chronic relapsing brucellosis as well as patients under treatment.

75 s the most cost-effective means of detecting brucellosis, as infection with smooth strains of Brucell

76 entation and pathophysiology of inhalational brucellosis, Balb/c mice were challenged with Brucella m

77 Human brucellosis can be acquired from infected animal tissues

78 Human brucellosis can be acquired from infected animal tissues

79 Brucellosis can be challenging to treat with conventiona

80 From 2015 to 2017, 11 confirmed brucellosis cases were reported in New York City, leadin

81 re was performed in 128 laboratory-confirmed brucellosis cases who had neurological symptoms and sign

82 demic institutes, resulting in >10 000 human brucellosis cases, as of November 2020.

83 We report the first case of brucellosis caused by an isolate whose genome is identic

84 id cells (ILCs) in the pathogenesis of focal brucellosis caused by Brucella melitensis.

85 Brucellosis caused by Brucella spp. is considered a debi

86 Brucellosis, caused by several species of the genus Bruc

87 tensis, one of the causative agents of human brucellosis, causes acute, chronic, and relapsing infect

88 abortus, the bacteria responsible for bovine brucellosis, causes chronic infections and abortions in

89 A mucosal vaccine against brucellosis consisting of the lipopolysaccharide (LPS) o

90 Vaccination remains a critical component of brucellosis control, but there are currently no vaccines

91 Detection of brucellosis currently relies on serologic testing of an

92 and tissue colonization in a mouse model of brucellosis, demonstrating that Brucella exploits the EP

93 Human patients with brucellosis develop recurrent fever and focal complicati

94 se, with the potential for new approaches to brucellosis diagnostics and understanding the immunopath

95 re higher in the border region for botulism, brucellosis, diphtheria, hepatitis A, measles, mumps, ra

96 d and specific laboratory diagnosis of human brucellosis directly from whole blood.

97 ospitalized were observed prospectively in a brucellosis-endemic region.

98 n worse condition after testing positive for brucellosis (F = -5.074, P < 0.0001), and infection was

99 ores the continuing serious health threat of brucellosis for Latinos in California, particularly olde

100 Specificity was evaluated by using 200 brucellosis-free nonvaccinated goats from 10 California

101 ts are at high risk of infection but data on brucellosis from these communities are scarce.

102 While T cell immunity in brucellosis has been extensively studied in mice, no rec

103 er Yellowstone Ecosystem (GYE), outbreaks of brucellosis have increased in cattle along with rising s

104 -cell-mediated immunity in control of murine brucellosis, however, is unknown.

105 es were to: estimate the prevalence of human brucellosis, identify the Brucella spp. causing illness,

106 Here we present a case of focal vertebral brucellosis in a 71-year-old Mexican-American woman who

107 ce and costs of serological assays for human brucellosis in a pastoralist community in northern Tanza

108 on patterns and fitness correlates of bovine brucellosis in African buffalo based on (1) 7 years of c

109 rtus, the infectious organism of the disease brucellosis in animals.

110 Reproductive failure is the hallmark of brucellosis in animals.

111 Genetically based natural resistance to brucellosis in cattle provides for novel strategies to c

112 udy revealed high seropositivity to RVFV and brucellosis in cattle, sheep, and goats that had recentl

113 tensis isolates from sporadic human cases of brucellosis in Egypt (n = 83), Qatar (n = 17), and Libya

114 am infections, and identify risk factors for brucellosis in febrile patients from a pastoralist commu

115 ificities of 17 antibody detection tests for brucellosis in goats were estimated.

116 unambiguous diagnostic antigen for detecting brucellosis in humans and animals and two hexasaccharide

117 eria that cause an infectious disease called brucellosis in humans and many domestic and wildlife ani

118 cellular bacteria, is the etiologic agent of brucellosis in humans and multiple animal species.

119 acultative intracellular bacteria that cause brucellosis in humans and other animals.

120 nts is the most common focal complication of brucellosis in humans.

121 flammation are common focal complications of brucellosis in humans; however, wild-type (WT) mice infe

122 e and herding, with a greater probability of brucellosis in individuals with lower age and who herded

123 intracellular bacterial pathogens that cause brucellosis in many animal species and humans.

124 The natural history of brucellosis in mice challenged by higher aerosol doses w

125 Brucella melitensis is the cause of brucellosis in sheep and goats, which often results in a

126 sus macaque (RM) as a model for inhalational brucellosis in support of the U.S. Food and Drug Adminis

127 ave potential to reduce the impacts of human brucellosis in Tanzania.

128 of commercial agglutination tests for human brucellosis in Tanzania.

129 ndings have applied implications for elk and brucellosis in the GYE.

130 contribution of B cells in control of murine brucellosis in the more susceptible BALB/c and the more

131 used as the official live vaccine for bovine brucellosis in the United States and several other count

132 Risk factors identified for brucellosis included age and herding, with a greater pro

133 infection leads to chronic and reactivating brucellosis, incurring significant morbidity and economi

134 Our results suggest that brucellosis infection can potentially result in reduced

135 Brucellosis is a bacterial zoonotic disease which has be

136 Human brucellosis is a common zoonosis worldwide.

137 Brucellosis is a globally significant zoonosis, the cont

138 Brucellosis is a globally significant zoonotic disease.

139 Brucellosis is a neglected zoonotic disease impacting ag

140 Brucellosis is a neglected zoonotic disease in most deve

141 Brucellosis is a severe occupational or foodborne zoonos

142 Brucellosis is a significant zoonotic disease throughout

143 Brucellosis is a worldwide disease of humans and livesto

144 Brucellosis is a zoonosis of nearly worldwide distributi

145 Brucellosis is a zoonotic disease caused by Gram-negativ

146 Brucellosis is a zoonotic disease with a worldwide distr

147 Brucellosis is a zoonotic infection caused primarily by

148 Brucellosis is an endemic zoonosis in sub-Saharan Africa

149 Brucellosis is an important zoonotic disease of nearly w

150 Human brucellosis is caused mainly by Brucella melitensis, whi

151 Brucellosis is characterized by abortion in ruminants an

152 In sub-Saharan Africa, brucellosis is considered endemic in many countries base

153 ost patients had traveled to countries where brucellosis is endemic and presented with histories and

154 efficacious immunization systems to prevent brucellosis is needed to overcome the disadvantages of t

155 for the bovine milk industry, to ensure that brucellosis is not introduced into the U.S. goat populat

156 Brucellosis is of great public health and economic impor

157 Brucellosis is the most common bacterial zoonosis, and c

158 Osteoarticular brucellosis is the most common complication in Brucella-

159 Brucella, the causative agent of brucellosis, is a stealthy intracellular pathogen that i

160 Five laboratory-acquired brucellosis (LAB) cases that occurred in the United Stat

161 commendations to prevent laboratory-acquired brucellosis (LAB) were followed; no seroconversions or L

162 d the characteristics of laboratory-acquired brucellosis (LAB).

163 Brucellosis, leptospirosis, Streptococcus and Moraxella

164 ue, Zika, yellow fever, chikungunya, rabies, brucellosis, melioidosis, and leptospirosis.

165 Brucellosis might have been transmitted via butchering o

166 port the use of the Balb/c aerosol nose-only brucellosis mouse model for the evaluation of therapeuti

167 Zoonotic transmission of brucellosis often results from exposure to Brucella-infe

168 ive bacteria that cause the zoonotic disease brucellosis, one of the most common global zoonoses.

169 la spp are intracellular bacteria that cause brucellosis, one of the most common zoonoses in the worl

170 was launched without the input of experts in brucellosis or Ochrobactrum; (iii) it applies a non-cons

171 the RMs in this study is analogous to human brucellosis pathophysiology.

172 from acute/subacute, blood culture-positive brucellosis patients but also recognized a distinct set

173 Human brucellosis patients develop flu-like symptoms and focal

174 Brucellosis poses a significant burden to human and anim

175 We report a case of brucellosis presenting as bacteraemia and aortic endarte

176 We investigated brucellosis, Q-fever and leptospirosis in the venous blo

177 Sera from this patient with chronic brucellosis recognized some of the same B. melitensis pr

178 d from domestic cattle in the United States, brucellosis remains a disease risk to people through acq

179 Cases of human brucellosis reported through the California public healt

180 -ranging elk are currently a self-sustaining brucellosis reservoir and the source of livestock infect

181 143 genomic DNA samples were extracted from brucellosis Rose Bengal plate test (RBPT) seropositive s

182 Annual brucellosis seroprevalence ranged from 8.7% (95% CI = 1.

183 and lambda = 1.00 (95% CI = 0.85-1.16) when brucellosis seroprevalence was 30%.

184 gens causing the worldwide zoonotic disease, brucellosis, that impacts economic growth of many countr

185 In patients with active brucellosis, the liver is frequently affected by histopa

186 f the RM as an animal model for inhalational brucellosis to evaluate the efficacy of novel vaccines a

187 the GYE to examine the differential risk of brucellosis transmission (through aborted foetuses) from

188 organism, as the clinicians did not consider brucellosis until they were notified that bacteremia wit

189 Thus, the optimal design for a brucellosis vaccine requires a nonliving vaccine that co

190 nt efforts have focused on developing a live brucellosis vaccine, and deletion of the znuA gene invol

191 ut also holds significance for the design of brucellosis vaccines and diagnostics that enable the dif

192 la may represent targets for improved, safer brucellosis vaccines and therapeutics.

193 stock testing positive for IgG antibodies to brucellosis was 36% [95% CI 25-49] in goats and 16% [95%

194 utant (BMEI 1364) as a vaccine candidate for brucellosis was conducted.

195 We find that brucellosis was introduced into wildlife in this region

196 No clinical evidence of brucellosis was seen in any goat.

197 In addition, the progression of brucellosis was similar between mice challenged by the i

198 From 1993 to 2017, 492 cases of brucellosis were reported in California residents.

199 the causative agent of the zoonotic disease brucellosis, which is endemic in many parts of the world

200 Patients with laboratory-confirmed brucellosis who were consequently hospitalized were obse